北卡罗来纳州，达勒姆市, June 28, 2024 (GLOBE NEWSWIRE) -- 全球领先的合同研究组织 (CRO) Fortrea (Nasdaq: FTRE) 今天宣布推出人工智能 (AI) 创新工作室，标志着该公司在重塑当今及未来临床试验执行方面的战略投资。 该工作室将开发和部署 AI 和机器学习 (ML) 技术，通过装备和授权人员专注于临床试验中关键的人为因素，提升临床研究过程中的速度、敏捷性、质量并增强患者安全性。 “全世界的患者都在等待改变生活的新颖疗法。有了 AI，我们现在有能力也有义务更快地为他们提供解决方案，”Fortrea 首席信息官 Alejandro Martinez Galindo 说道。 “Fortrea 的 AI 创新工作室将增强技术能力，使 AI 赋能系统能够执行先进流程，如试验模拟、预测分析和模式识别，以及重复性、管理性、‘机器友好型任务’。如此一来，人们就可以解放出来，为未来的临床试验贡献人类的创造力和联系，并专注于最重要的事情：患者。” Fortrea 的 AI 创新工作室旨在： 在 Fortrea 内部以及与我们的客户合作，为定制研究中心和申办者创新战略提供 ...

The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research process by equipping and empowering people to focus on the critical human element of clinical trials. "Fortrea's AI Innovation Studio will enable enhanced technological capabilities that will allow AI-enabled systems to perform cutting-edge processes—such as trial simulations, predictive analytics and pattern recognition—as well as repetitive, adm ...

DURHAM, N.C., June 19, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Chief Financial Officer Jill McConnell will participate in a virtual fireside chat hosted by Elizabeth Anderson, senior managing director at Evercore ISI, to discuss Fortrea's business on Thursday, June 20, 2024 at 2:00 pm ET. Registration for the live event is required here. The event is scheduled for 30 minutes. A replay will be available by accessing the Fortr ...

DURHAM, N.C., June 19, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Chief Financial Officer Jill McConnell will participate in a virtual fireside chat hosted by Elizabeth Anderson, senior managing director at Evercore ISI, to discuss Fortrea's business on Thursday, June 20, 2024 at 2:00 pm ET. About Fortrea Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com Sue Zaranek (Media) – 919-943-5422, media@fortrea.com Kate D ...

DURHAM, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) a leading global contract research organization ("CRO"), today announced it has completed the divestiture of assets relating to its Enabling Services segment, namely its Endpoint Clinical ("Endpoint") and Fortrea Patient Access ("FPA") businesses, to Arsenal Capital Partners ("Arsenal"), a leading private equity firm specializing in building market-leading, technology-rich healthcare and industrial growth companies. Endpoint and FPA prov ...

DURHAM, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) a leading global contract research organization ("CRO"), today announced it has completed the divestiture of assets relating to its Enabling Services segment, namely its Endpoint Clinical ("Endpoint") and Fortrea Patient Access ("FPA") businesses, to Arsenal Capital Partners ("Arsenal"), a leading private equity firm specializing in building market-leading, technology-rich healthcare and industrial growth companies. Endpoint and FPA prov ...

Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea. DURHAM, N.C., June 0 ...

Core Insights - Fortrea, a leading global contract research organization (CRO), will present at the Jefferies Global Healthcare Conference on June 5, 2024 [1] - The live webcast of the presentation will be accessible via the Fortrea Investor Relations website, with a replay available post-event [2] Company Overview - Fortrea specializes in clinical development and patient access solutions for the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [3] - The company offers a range of services including phase I-IV clinical trial management, clinical pharmacology, consulting services, and post-approval services [3] - Fortrea has over three decades of experience across more than 20 therapeutic areas, emphasizing scientific rigor and a strong investigator site network [4] - The company operates in over 90 countries, providing agile solutions to its global customer base [4]

利用真实世界数据、患者见解和系统化的流程，设计、实施和衡量临床试验中多样性行动计划的作用北卡罗来纳州，达勒姆, June 01, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) （以下简称“公司”）, 一家全球领先的合同研究组织 (CRO) ，今天宣布推出全面的综合解决方案，以改善临床试验参与者的多样性和入选 (D&I)。Fortrea 的 D&I 解决方案旨在增加患者参与临床试验的机会，并满足美国食品药品监督管理局 (FDA) 在《食品和药品综合改革法案》下提出的要求，增加临床试验中代表性不足群体参与。 Fortrea 的综合流程整合了多元化行动计划和执行的五个组成部分： 真实世界证据顾问研究相关的真实世界数据集，为多样性计划提供信息。法规、开发和临床运营专家设计多样性行动计划，与患者群体确认并与监管方谈判。运营团队访问多个数据平台、Fortrea 的现场咨询委员会和技术驱动解决方案，将多样性行动计划作为 Fortrea 临床试验执行的一个必要组成部分来实施。通过 Fortrea 独家的多样性和入选研究洞察板，实现监测和报告，提供可操作数据和可视化工具，以进行 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 001-41704 FORTREA HOLDINGS INC. (Exact name of registrant as specified in its charter) INDEX | Delaware | 92-2796441 | | --- | -- ...